Get Your Personalized Supplement StackSupplement Stack Quiz

EDTA Disodium

Also known as: Ethylenediaminetetraacetic acid, EDTA, Edetate disodium, Disodium EDTA

Overview

Ethylenediaminetetraacetic acid (EDTA) is a synthetic chelating agent primarily used to bind and remove metal ions from the body. It is not found naturally and is commonly used in medical settings to treat heavy metal toxicities, such as lead poisoning. EDTA is effective in chelating divalent and trivalent metal ions, making it useful for removing toxic metals. While its primary application is in treating metal poisoning, EDTA has also been explored for its potential in treating atherosclerotic cardiovascular disease. The use of EDTA in cardiovascular disease treatment is still under investigation, with studies showing mixed results. EDTA is typically administered intravenously, ensuring high bioavailability, while oral administration is less effective due to poor absorption. Research on EDTA's effectiveness in treating cardiovascular diseases is ongoing, with systematic reviews and meta-analyses providing varying degrees of support.

Benefits

EDTA chelation therapy has shown potential benefits in treating atherosclerotic cardiovascular disease. A systematic review and meta-analysis indicated improved outcomes in some studies, though the evidence is limited by methodological variability. The Trial to Assess Chelation Therapy (TACT) suggested that EDTA infusions might reduce composite cardiovascular outcomes, such as death, reinfarction, stroke, coronary revascularization, or hospitalization for angina, but the significance was modest. Some studies also suggest improvements in subjective measures, but these findings are inconsistent. The benefits appear more pronounced in patients with a history of myocardial infarction and those with atherosclerotic cardiovascular disease. However, the effect sizes are generally modest, and the clinical significance remains debated due to mixed results and methodological limitations. Long-term follow-up data, such as the 5-year follow-up in the TACT study, suggest potential long-term benefits, but more consistent data are needed.

How it works

EDTA functions by chelating metal ions, particularly calcium, which is believed to help reduce the progression of atherosclerosis. This process involves binding to metal ions like calcium, lead, and mercury, facilitating their excretion from the body. EDTA primarily interacts with the cardiovascular system, potentially improving blood flow and reducing the severity of atherosclerotic plaques by removing calcium deposits from arterial walls. When administered intravenously, EDTA exhibits high bioavailability, allowing it to effectively bind to and remove targeted metal ions. Oral administration is less effective due to poor absorption, making intravenous delivery the preferred method for therapeutic applications.

Side effects

EDTA is generally considered safe when used appropriately, but it carries potential side effects and contraindications. Common side effects include renal impairment, due to its impact on kidney function, and hypocalcemia, resulting from the chelation of calcium ions. Local reactions at the infusion site are also frequently observed. Uncommon side effects range from allergic reactions and gastrointestinal disturbances to fatigue. Rare but severe side effects include severe renal damage and cardiac arrhythmias. EDTA can interact with medications affecting calcium levels or renal function and should be used cautiously with anticoagulants. Contraindications include severe renal impairment, active kidney disease, and pregnancy or breastfeeding due to limited safety data. Special consideration should be given to patients with compromised renal function and elderly patients, who may require dose adjustments to mitigate potential renal impairment.

Dosage

EDTA is typically administered intravenously in doses ranging from 1 to 3 grams per infusion, depending on the specific indication and patient condition. For cardiovascular disease, the TACT study used 40 intravenous infusions of disodium EDTA, with the first 30 infusions given weekly and the remaining 10 infusions given 2 to 8 weeks apart. The maximum safe dose is generally 3 grams per infusion, but this can vary based on individual patient factors and renal function. Infusions are typically given over several hours to minimize side effects. Intravenous administration is the most common and effective method, as oral absorption is poor. While no specific cofactors are required, patients often receive oral high-dose vitamins and minerals in conjunction with EDTA infusions.

FAQs

How is EDTA chelation therapy administered?

EDTA chelation therapy is administered intravenously in a clinical setting, requiring monitoring. Patients should be aware of potential renal impairment and the need for regular kidney function tests. It is not a substitute for standard cardiovascular treatments.

Is EDTA chelation therapy safe?

While generally safe, EDTA can cause significant side effects, especially related to calcium levels and renal function. Close monitoring by a healthcare provider is essential to mitigate potential risks.

How often are EDTA infusions given?

Infusions are usually given weekly or biweekly, depending on the treatment protocol. The duration of treatment can range from several months to years, depending on the individual's condition and response to therapy.

What are the expected results from EDTA chelation therapy?

Patients may experience improved cardiovascular outcomes, but the evidence is mixed, and individual results can vary. Regular follow-up and monitoring are necessary to assess the effectiveness and safety of the treatment.

Is EDTA chelation therapy a proven cure for cardiovascular disease?

No, EDTA chelation therapy is not a proven cure for cardiovascular disease and should not be used as a replacement for established treatments. It is primarily used in a medical setting under the supervision of a healthcare provider.

Research Sources

https://www.southcarolinablues.com/web/public/brands/medicalpolicy/external-policies/chelation-therapy-for-off-label-uses/ – This source provides a general overview of chelation therapy and its off-label uses. It likely discusses the controversies and limitations associated with using chelation therapy for conditions other than heavy metal poisoning, highlighting the need for further research to validate its effectiveness and safety.
https://journals.lww.com/md-journal/Fulltext/2020/12240/Evaluation_on_curative_effects_of_ethylene_diamine.7.aspx – This study protocol outlines a systematic review and meta-analysis aimed at assessing the curative effects of EDTA chelation therapy in patients with atherosclerotic cardiovascular disease. The protocol details the methodology for evaluating the available evidence, including the criteria for study selection, data extraction, and analysis, to determine the potential benefits and risks of EDTA chelation therapy for cardiovascular conditions.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002785.pub2/full – This Cochrane review evaluates the effectiveness of EDTA chelation therapy for cardiovascular disease. The review analyzes data from multiple randomized controlled trials to assess the impact of EDTA chelation on cardiovascular outcomes, considering factors such as mortality, morbidity, and quality of life, while also addressing potential biases and limitations in the available evidence.
https://subjectguides.lib.neu.edu/systematicreview/databases – This resource provides guidance on conducting systematic reviews, including information on relevant databases and search strategies. It assists researchers in identifying and synthesizing evidence from multiple studies to address specific research questions, ensuring a comprehensive and unbiased assessment of the available literature.
https://archive.hshsl.umaryland.edu/bitstream/handle/10713/12104/EDTA_Final_2020_02.pdf?sequence=6 – This document provides a comprehensive overview of EDTA, including its chemical properties, mechanisms of action, and clinical applications. It covers the use of EDTA in various medical settings, including the treatment of heavy metal poisoning and potential applications in cardiovascular disease, while also addressing safety considerations and potential side effects.